• linkedin
  • Increase Font
  • Sharebar

    Liver transplant recipients with HCV fare well under drug combo

    For post-liver transplant recipients infected with hepatitis C virus (HCV), a combination of ledipasvir and sofosbuvir without ribavirin yields excellent outcomes and favorable safety and tolerability profiles, according to a new study.

    Current guidelines recommend including ribavirin when treating post-transplant patients because of a lack of efficacy data of therapies without ribavirin.

    “This study, the largest single-center experience of post-liver transplant patients with HCV genotype 1 recurrence taking direct-acting antivirals (DAAs) without ribavirin, is uniquely designed to determine the effectiveness of DAAs in post-transplant patients without ribavirin,” Joel Wedd MD, MPH, assistant professor of medicine and director of the Liver Tumor Clinic at Atlanta-based Emory University Hepatology and Liver Transplantation, told Medical Economics.

    This is particularly important because ribavirin has side effects, especially in the post-transplant population, he noted.

    The researchers published their results in the June 2017 Alimentary Pharmacology & Therapeutics.

    Next: Study details

    Mark L. Fuerst
    Staff Correspondent

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow